Drug Profile
Inupadenant - iTeos Therapeutics
Alternative Names: EOS-100850; EOS-850; Inupadenant hydrochlorideLatest Information Update: 16 May 2023
Price :
$50
*
At a glance
- Originator iTeos Therapeutics
- Class 3-ring heterocyclic compounds; Amines; Antineoplastics; Fluorobenzenes; Furans; Organic sulfur compounds; Piperazines; Pyrimidines; Small molecules; Thiazoles
- Mechanism of Action Adenosine A2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Malignant melanoma; Non-small cell lung cancer
- Phase I/II Solid tumours
Most Recent Events
- 10 May 2023 Pharmacodynamics data from a preclinical trial in Cancer released by iTeos Therapeutics
- 28 Apr 2023 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in United Kingdom (PO)
- 15 Mar 2023 iTeos Therapeutics completes enrolment in a phase IIa trials in Malignant melanoma (Combination therapy) (unspecified route)